ADIPOQ and metabolic dysfunction-associated steatohepatitis: Significantly decreased NASH-related biomarkers (ALT, cytokeratin-18, procollagen III) and increased adiponectin in patients with T2D. Patients received subcutaneously doses of tirzepatide (1, 5, 10, 15 mg) once a week for 26 weeks (148).